Richard Lafayette, MD, FACP

Richard Lafayette, MD, FACP, explains why a REMS program is not required for the endothelin A receptor antagonist and how patients may need to adjust should final ALIGN trial data fail to show a clinical benefit of atrasentan.

Richard Lafayette, MD, FACP, Stanford University Medical Center, explains the significance of this second approval in a month for proteinuria reduction.